Guardant Health (GH)
NASDAQ:GH
Want to see GH full AI Analyst Report?
GH Stock Chart & Stats
$90.36
$0.91(2.52%)
At close: 4:00 PM EST
$90.36
$0.91(2.52%)
Day’s Range― - ―
52-Week Range$40.36 - $135.00
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.43M
Market Cap
$17.47B
Enterprise Value$17.84B
Total Cash (Recent Filing)$1.10B
Total Debt (Recent Filing)$1.70B
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Jul 30, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.39
Shares Outstanding132,599,930
10 Day Avg. Volume2,247,771
30 Day Avg. Volume2,428,746
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue16.51
Enterprise Value/Gross Profit25.44
Enterprise Value/Ebitda-45.62
Forecast
1Y Price Target
$143.39Price Target Upside58.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)-2.93
Revenue Forecast (FY)$1.31B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Commercial TractionGuardant's strong top-line momentum and raised guidance reflect durable commercial adoption: Q1 showed sizable YoY growth and management now targets >32% revenue growth for 2026. Scaling oncology test volumes and broader channel launches provide multi-quarter runway to convert demand into recurring clinical and biopharma revenue.
Gross Margin Improvement From Sequencing Cost ReductionsStructural cost reductions from transitioning to NovaSeq X materially lower per-test COGS, delivering higher gross margins that persist as volumes scale. Sequencing savings plus targeted Shield per-test cost declines support sustainable margin expansion across products as utilization and throughput increase.
Proprietary Data & Biopharma PartnershipsA large, proprietary dataset and AI platform create a durable competitive moat: the data treasury supports companion diagnostics, real-world evidence services and smart-app development, strengthening long-term ties with biopharma partners and enabling recurring, higher-margin data-driven revenue streams over multiple years.
Bears Say
High Leverage & Negative EquityMaterial leverage and negative shareholders' equity weaken balance-sheet resilience and constrain strategic flexibility. High debt increases refinancing and interest risks and limits the firm's capacity to absorb shocks or pursue inorganic growth without dilutive financing, a persistent constraint until sustained profitability accumulates equity.
Continued Negative Cash Flow And FCF BurnOngoing operating and free-cash-flow deficits mean the company remains reliant on cash reserves or external financing to fund growth. While burn is improving and management targets breakeven by end-2027, the multi-quarter funding requirement increases execution risk and can constrain investment pacing if markets tighten or cash drawdown accelerates.
Reimbursement & Regulatory DependencyCommercial upside for screening and some monitoring uses depends on regulatory and payer milestones (MolDx reviews, ACS guideline inclusion, commercial coverage). These external, timing-sensitive decisions can materially delay revenue realization and ASP normalization, making growth contingent on outcomes outside direct operational control.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $40.35 and its highest was $135.00 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $17.47B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Jul 30, 2026 which is in 38 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on May 07, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.806 by -$0.044.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.75.
How many shares outstanding does Guardant Health have?
Guardant Health has 132,599,930 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.806. Following the earnings report the stock price went up 3.729%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$143.39 (58.69% Upside)
$143.39 (58.69% Upside)
Blogger Sentiment
Bullish
GH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 808.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $52.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
160.58%
12-Months-Change
Fundamentals
Return on Equity
184.27%
Trailing 12-Months
Asset Growth
42.48%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
GH Company Deck
GH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and commercial quarter: revenue growth was robust across Oncology, Biopharma & Data and Screening, Shield showed breakout traction with meaningful margin improvement, and product and data investments (InfinityAI, NovaSeq X transition, expanded FDA approvals and partnerships) support multi-year upside. Key near-term challenges include elevated operating expenses to fund growth, ongoing adjusted losses and free cash flow burn, and dependencies on reimbursement and third-party regulatory outcomes (MolDx reviews, drug approvals) that introduce timing and upside uncertainty. Overall, positives (accelerating revenue, volume, margin improvement, data/AI progress, and strengthened partnerships) materially outweigh the risks, though execution and reimbursement milestones remain important to sustain momentum.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$143.39
▲(58.69% Upside)
Technical Analysis
Ownership Overview
3.25% Insiders
32.42% Mutual Funds
35.53% Other Institutional Investors
12.81% Public Companies and
Individual Investors